title: Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells.
abstract: Inherent resistance of colon cancer cells to cis-diamminedichloroplatinum(II) (CDDP) is partly attributed to reduced drug penetration through plasma membrane. Amphotericin B (AmB), a polyene antifungal antibiotic, has been shown to increase CDDP penetration and cytotoxicity on several non-digestive cancer cell lines. We demonstrated here that AmB dramatically increases the penetration of CDDP, and to a lesser extent that of carboplatin (Carbo-P) and oxaloplatin (L-OHP), in the primary resistant HT 29 human colon cancer cells when drug incubation is performed in serum-free medium. The cytotoxicity of CDDP but not that of Carbo-P and L-OHP was increased by AmB. However, AmB-induced potentiation of CDDP penetration and toxicity was almost completely abolished when cell incubation was performed in presence of human serum. We investigated whether the dilution of human serum by a high osmotic power gelatine solution (Lomol) could restore the positive effect of AmB on CDDP accumulation in HT 29 cells. Incubation of cells with CDDP and AmB in pure Lomol resulted in a 6-fold increase in platinum cellular content. However, addition of serum (25%) in Lomol solution reduced to only 2-fold the increase in platinum cellular content provoked by AmB. These disappointing results show that AmB is probably uninteresting as a modulator of CDDP resistance in clinical practice. The use of haemodilution to restore the positive AmB effect on platinum cellular accumulation cannot be warranted.
authors.affiliation: INSERM U252, Faculté de Médecine, Dijon, France.
authors.forename: M
authors.initials: M
authors.lastname: Assem
authors.forename: S
authors.initials: S
authors.lastname: Bonvalot
authors.forename: J L
authors.initials: JL
authors.lastname: Beltramo
authors.forename: C
authors.initials: C
authors.lastname: Garrido
authors.forename: M T
authors.initials: MT
authors.lastname: Dimanche-Boitrel
authors.forename: P
authors.initials: P
authors.lastname: Genne
authors.forename: J M
authors.initials: JM
authors.lastname: Rebibou
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: B
authors.initials: B
authors.lastname: Chauffert
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000666:Amphotericin B / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000633:toxicity; D001798:Blood Proteins / Q000494:pharmacology*; D002463:Cell Membrane Permeability / Q000187:drug effects; D002945:Cisplatin / Q000493:pharmacokinetics* / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D016895:Culture Media, Serum-Free; D004351:Drug Resistance; D004357:Drug Synergism; D006801:Humans; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D001798:Blood Proteins; D016895:Culture Media, Serum-Free; D000666:Amphotericin B; D002945:Cisplatin